Contemporary opioid use disorder management requires matching medication formulation to individual patient circumstances, considering adherence patterns, care access barriers, stigma exposure, and recovery phase.1,2 Treatment selection increasingly balances pharmacologic effectiveness with real-world feasibility, recognizing that sustained engagement determines outcomes more than theoretical efficacy alone.
Extended-release subcutaneous buprenorphine exemplifies this evolution, addressing adherence barriers by maintaining steady-state plasma levels through partial mu-opioid receptor agonism.2 Monthly and weekly injection options eliminate daily decision points while providing consistent medication exposure.2 Common adverse reactions include injection-site pain, erythema, and pruritus, alongside systemic effects including headache, constipation, nausea, insomnia, and urinary tract infection.2 Clinicians should also assess factors such as a patient’s current fertility status and potential interactions with other medications or substance to ensure safe and individualized therapy.
Buprenorphine’s pharmacologic profile extends beyond addiction treatment into perioperative and acute pain management for medically complex populations.3 Its partial mu-opioid agonism is associated with a ceiling effect on respiratory depression and may confer a comparatively favorable safety profile relative to full agonists in selected populations.3 This supports expanded continued exploration of application in multimodal pain strategies for elderly, cardiac, renal, and other high-risk surgical patients.
Emerging technologies and pharmacologic agents may further reshape OUD treatment. Machine learning algorithms analyzing electronic health record data show promise for identifying patients at elevated risk for opioid misuse, potentially informing earlier intervention strategies, though current models require external validation before widespread hospital implementation.4 Clinical trials are exploring combined pharmacological and behavioral approaches to improve treatment retention and identify patients who may safely discontinue medications for opioid use disorder (MOUD) with minimized relapse risk.5 Novel compounds under investigation include first-in-class dual mu-opioid receptor partial agonist and delta-opioid receptor full antagonist mechanisms of action for treating opioid use disorder and withdrawal syndrome, representing potential future alternatives to current MOUD options.6
Take our opioid use disorder quiz to see how your knowledge compares to your peers.
